High throughput screening strategies and technology platforms for detection of pathogens

2015 ◽  
pp. 1-9
Author(s):  
A.K. Bhunia ◽  
C.R. Taitt ◽  
M.S. Kim
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Technology Platforms ◽  
Screening Strategies

scholarly journals Stratified High-Throughput Screening Sets Enable Flexible Screening Strategies from a Single Plated Collection

2013 ◽  
Vol 19 (3) ◽  
pp. 369-378 ◽  
Author(s):  
J.Willem M. Nissink ◽  
Stefan Schmitt ◽  
Sam Blackburn ◽  
Stephen Peters
Keyword(s):  
Cost Saving ◽  
High Throughput ◽  
High Throughput Screening ◽  
Substantial Cost ◽  
Substantial Cost Saving ◽  
Set Size ◽  
Screening Strategies

Customized compound picking and plating of very large corporate screening decks (many 100,000s) for high-throughput screening is generally restricted, both from a time and cost perspective. Here we present a stratified screening deck with accompanying plating design for use with very large corporate compound collections. The deck is plated as a whole, but copies for screening can be downsized flexibly and quickly on the fly, without the need for repicking of physical samples. We show that such downsized sets maximize returns and yield results superior to randomly picked subsets of the same size. For the proposed stratified plating design, structurally diverse subsets that cover the full collection in terms of compound diversity and favorable compound properties can be produced economically and quickly from the full set of master plates. The design was implemented globally at AstraZeneca in 2009 and has enabled substantial cost-saving in screening campaigns, as set size requirements can be met on a per-screen basis, using a single, preplated master deck.

scholarly journals Process Validation and Screen Reproducibility in High-Throughput Screening

2008 ◽  
Vol 14 (1) ◽  
pp. 66-76 ◽  
Author(s):  
Isabel Coma ◽  
Liz Clark ◽  
Emilio Diez ◽  
Gavin Harper ◽  
Jesus Herranz ◽  
...  
Keyword(s):  
Drug Discovery ◽  
High Throughput ◽  
High Throughput Screening ◽  
Large Scale ◽  
Academic Community ◽  
Major Step ◽  
Chemical Genomic ◽  
Screening Strategies ◽  
Medical Diagnostic ◽  
Compound Screening

The use of large-scale compound screening has become a key component of drug discovery projects in both the pharmaceutical and the biotechnological industries. More recently, these activities have also been embraced by the academic community as a major tool for chemical genomic activities. High-throughput screening (HTS) activities constitute a major step in the initial drug discovery efforts and involve the use of large quantities of biological reagents, hundreds of thousands to millions of compounds, and the utilization of expensive equipment. All these factors make it very important to evaluate in advance of the HTS campaign any potential issues related to reproducibility of the experimentation and the quality of the results obtained at the end of these very costly activities. In this article, the authors describe how GlaxoSmithKline (GSK) has addressed the need of a true validation of the HTS process before embarking in full HTS campaigns. They present 2 different aspects of the so-called validation process: (1) optimization of the HTS workflow and its validation as a quality process and (2) the statistical evaluation of the HTS, focusing on the reproducibility of results and the ability to distinguish active from nonactive compounds in a vast collection of samples. The authors describe a variety of reproducibility indexes that are either innovative or have been adapted from generic medical diagnostic screening strategies. In addition, they exemplify how these validation tools have been implemented in a number of case studies at GSK. ( Journal of Biomolecular Screening 2009:66-76)

Transfected Cell Lines as Tools for High Throughput Screening: A Call for Standards

2001 ◽  
Vol 6 (3) ◽  
pp. 133-136 ◽  
Author(s):  
Len Pagliaro ◽  
Morten Præstegaard
Keyword(s):  
Cell Lines ◽  
High Throughput ◽  
High Throughput Screening ◽  
Target Identification ◽  
Complex Variables ◽  
Screening System ◽  
Library Size ◽  
Global Issues ◽  
Screening Strategies ◽  
Assay Design

During 1999, Journal of Biomolecular Screening presented a series of Point-Counterpoint articles that addressed a question posed by editor Bill Janzen: "What is the future of HTS?" These articles discussed many of the global issues involved in HTS, such as target identification and library size, as well as the scientific and technical challenges facing the field. In this perspective we address a related, but very focused, issue that is increasingly important for many of us in the HTS community: the use of stably transfected cell lines as an integral part of screening strategies. Transfected cell lines provide powerful tools for assay design, but at the same time they introduce complex variables into the screening system. Although it is difficult to develop precise definitions and standards for biologicals such as cell lines, we propose that the development of guidelines for the nomenclature and use of transfected cell lines is essential for their use in HTS.

scholarly journals Phenotypic Screening in C. elegans as a Tool for the Discovery of New Geroprotective Drugs

2020 ◽  
Vol 13 (8) ◽  
pp. 164 ◽  
Author(s):  
Sven Bulterijs ◽  
Bart P. Braeckman
Keyword(s):  
High Throughput ◽  
High Throughput Screening ◽  
Aging Process ◽  
Population Aging ◽  
Model Organisms ◽  
Pharmacological Interventions ◽  
C Elegans ◽  
System A ◽  
Age Related ◽  
Screening Strategies

Population aging is one of the largest challenges of the 21st century. As more people live to advanced ages, the prevalence of age-related diseases and disabilities will increase placing an ever larger burden on our healthcare system. A potential solution to this conundrum is to develop treatments that prevent, delay or reduce the severity of age-related diseases by decreasing the rate of the aging process. This ambition has been accomplished in model organisms through dietary, genetic and pharmacological interventions. The pharmacological approaches hold the greatest opportunity for successful translation to the clinic. The discovery of such pharmacological interventions in aging requires high-throughput screening strategies. However, the majority of screens performed for geroprotective drugs in C. elegans so far are rather low throughput. Therefore, the development of high-throughput screening strategies is of utmost importance.

Sign in / Sign up

Export Citation Format

Share Document